{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:18:09Z","timestamp":1788247089704,"version":"build-2803163510"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>Zhou and colleagues identify mitochondrial complex I activity, mediated through NDUFA9, as a critical determinant of natural killer (NK) cell metabolic fitness and antitumor function in glioblastoma. Their study links impaired oxidative phosphorylation to glutamine dependence, epigenetic repression of effector programs, and loss of NK cell activity, highlighting mitochondrial fitness as an actionable axis for improving cellular immunotherapy in solid tumors.<\/jats:p>\n                  <jats:p>See related article by Zhou et al., p. 1924<\/jats:p>","DOI":"10.1158\/2159-8290.cd-26-1267","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:08:58Z","timestamp":1788246538000},"page":"1727-1729","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitochondrial Complex I at the Crossroads of NK cell Dysfunction in Glioblastoma"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-2365","authenticated-orcid":false,"given":"Silvia","family":"Tiberti","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Stem Cell Transplantation and Cellular Therapy, , Houston, Texas."},{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Institute for Cell Therapy Discovery and Innovation, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9599-2246","authenticated-orcid":false,"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Stem Cell Transplantation and Cellular Therapy, , Houston, Texas."},{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Institute for Cell Therapy Discovery and Innovation, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6026-8397","authenticated-orcid":false,"given":"May","family":"Daher","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Stem Cell Transplantation and Cellular Therapy, , Houston, Texas."},{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Institute for Cell Therapy Discovery and Innovation, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026090103083864700_bib1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"2026090103083864700_bib2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090103083864700_bib3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102881","article-title":"Advancing CAR-NK cell therapy in solid tumors: current landscape and future directions","author":"Manzar","year":"2026  25","journal-title":"Cell Rep Med"},{"key":"2026090103083864700_bib4","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.cmet.2021.03.023","article-title":"Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment","volume":"33","author":"Poznanski","year":"2021","journal-title":"Cell Metab"},{"key":"2026090103083864700_bib5","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/s41590-019-0511-1","article-title":"Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance","volume":"20","author":"Zheng","year":"2019","journal-title":"Nat Immunol"},{"key":"2026090103083864700_bib6","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1158\/2159-8290.CD-25-0643","article-title":"Correcting mitochondrial complex I defect in tumor-associated natural killer cells potentiates immunotherapy for glioblastoma","volume":"16","author":"Zhou","year":"2026","journal-title":"Cancer Discov"},{"key":"2026090103083864700_bib7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026090103083864700_bib8","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","article-title":"Engineered natural killer cells for cancer therapy","volume":"43","author":"Biederst\u00e4dt","year":"2025","journal-title":"Cancer Cell"},{"key":"2026090103083864700_bib9","doi-asserted-by":"publisher","first-page":"eaeb1459","DOI":"10.1126\/sciimmunol.aeb1459","article-title":"Palmitate-induced mitochondrial damage restricts histone acetylation in CD8 T cells to impair antitumor immunity","volume":"11","author":"Tiberti","year":"2026","journal-title":"Sci Immunol"},{"key":"2026090103083864700_bib10","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","article-title":"Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD","volume":"42","author":"Shanley","year":"2024","journal-title":"Cancer Cell"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/9\/1727\/3824475\/cd-26-1267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/9\/1727\/3824475\/cd-26-1267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:08:59Z","timestamp":1788246539000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/9\/1727\/787661\/Mitochondrial-Complex-I-at-the-Crossroads-of-NK"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":10,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-26-1267","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}